{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:04:18Z","timestamp":1791165858495,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is a lack of consensus regarding the optimal method of assessing health-related quality of life (HR-QOL) among patients with metastatic renal cell carcinoma (mRCC). This study explored the perceived relevance of items that make up the Functional Assessment of Cancer Therapy Kidney Symptom Index-19 (FKSI-19), as judged by patients with mRCC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a multinational cross-sectional survey. Eligible patients responded to a questionnaire composed of 18 items that assessed the perceived relevance of each item in the FKSI-19 questionnaire. Open-ended questions assessed additional issues deemed relevant by patients. Responses were grouped as relevant (scores 2-5) or nonrelevant (score 1). Descriptive statistics were collated, and open-ended questions were analyzed and categorized into descriptive categories. Spearman correlation statistics were used to test the association between relevance and clinical characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 151 patients were included (gender: 78.1 M, 21.9F; median age: 64; treatment: 38.4 immunotherapy, 29.8 targeted therapy, 13.9 immuno-TKI combination therapy) in the study. The most relevant questions evaluated fatigue (77.5), lack of energy (72.2), and worry that their condition will get worse (71.5). Most patients rated blood in urine (15.2), fevers (16.6), and lack of appetite (23.2) as least relevant. Qualitative analysis of open-ended questions revealed several themes, including emotional and physical symptoms, ability to live independently, effectiveness of treatment, family, spirituality, and financial toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>There is a need to refine widely used HR-QOL measures that are employed among patients diagnosed with mRCC treated with contemporary therapies. Guidance was provided for the inclusion of more relevant items to patients\u2019 cancer journey.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad028","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T19:18:54Z","timestamp":1678821534000},"page":"494-500","source":"Crossref","is-referenced-by-count":13,"title":["Patients\u2019 Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0037-0303","authenticated-orcid":false,"given":"Cristiane Decat","family":"Bergerot","sequence":"first","affiliation":[{"name":"Centro de C\u00e2ncer de Bras\u00edlia, Instituto Unity de Ensino e Pesquisa , Bras\u00edlia, DF , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasnoor","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center , Duarte, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Bergerot","sequence":"additional","affiliation":[{"name":"Centro de C\u00e2ncer de Bras\u00edlia, Instituto Unity de Ensino e Pesquisa , Bras\u00edlia, DF , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Errol J","family":"Philip","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California San Francisco , San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela V","family":"Castro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center , Duarte, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center , Duarte, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto Cesar de Andrade","family":"Mota","sequence":"additional","affiliation":[{"name":"Medical Oncology, Clinica AMO , Salvador , BA , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andressa","family":"Cardoso de Azeredo","sequence":"additional","affiliation":[{"name":"Medical Oncology, Instituto de Oncologia Kaplan , Porto Alegre , RS , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Nunes de Matos","family":"Neto","sequence":"additional","affiliation":[{"name":"Centro de C\u00e2ncer de Bras\u00edlia, Instituto Unity de Ensino e Pesquisa , Bras\u00edlia, DF , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hutson","sequence":"additional","affiliation":[{"name":"Urologic Oncology Program, Texas Oncology at Baylor Sammons Cancer Center , Dallas, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[{"name":"Clinic for Medical Oncology, Clinic for Urology, University Hospital Essen , Essen, Alemanha, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bex","sequence":"additional","affiliation":[{"name":"UCL Division of Surgical and Interventional Science, The Netherlands Cancer Institute , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P","family":"Psutka","sequence":"additional","affiliation":[{"name":"Urology Clinic, University of Washington , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Rini","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt-Ingram Cancer Center , Nashville, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R","family":"Plimack","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology and Chief, Fox Chase Cancer Center , Philadelphia, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj","family":"Master","sequence":"additional","affiliation":[{"name":"Department of Urology, Emory University Hospital , Atlanta, GA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5734-3480","authenticated-orcid":false,"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy Institute , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Lank Center for Genitourinary (GU) Oncology, Dana-Farber Cancer Institute , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center , Duarte, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[{"name":"Barts Cancer Centre, Barts Cancer Centre at St. Bartholomew\u2019s Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"issue":"14","key":"2023060913460065200_CIT0001","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"2023060913460065200_CIT0002","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"2023060913460065200_CIT0003","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"2023060913460065200_CIT0004","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"2023060913460065200_CIT0005","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"2023060913460065200_CIT0006","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(18)30778-2","article-title":"Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate214): a randomized, phase 3 trial","volume":"20","author":"Cella","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"2023060913460065200_CIT0007","first-page":"427","article-title":"Health-related quality of life (HRQoL) analysis from KEYNOTE-426: pembrolizumab (pembro) plus axitinib (axi) vs sunitinib for advanced renal cell carcinoma (RCC)","volume":"82","author":"Bedke","year":"2022","journal-title":"35th Annual EAU Congress"},{"issue":"2","key":"2023060913460065200_CIT0008","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(21)00693-8","article-title":"Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomized, phase 3 trial","volume":"23","author":"Cella","year":"2022","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"2023060913460065200_CIT0009","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2021.39.15_suppl.4502","article-title":"Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of Lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"39","author":"Motzer","year":"2021","journal-title":"J Clin Oncol."},{"issue":"12","key":"2023060913460065200_CIT0010","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med."},{"issue":"1","key":"2023060913460065200_CIT0011","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.euf.2019.02.020","article-title":"Patient-reported outcome measures in metastatic urinary cancers","volume":"6","author":"Bergerot","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"4","key":"2023060913460065200_CIT0012","first-page":"191","article-title":"Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)","volume":"4","author":"Cella","year":"2006","journal-title":"J Support Oncol."},{"issue":"9","key":"2023060913460065200_CIT0013","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s11136-021-02839-9","article-title":"A psychometric evaluation of the Functional assessment of cancer therapy-kidney symptom index (FKSI-19) among renal cell carcinoma patients suggesting an alternative two-factor structure","volume":"30","author":"Rosenblad","year":"2021","journal-title":"Qual Life Res"},{"issue":"6","key":"2023060913460065200_CIT0014","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S1470-2045(18)30125-6","article-title":"Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology","volume":"19","author":"Kanesvaran","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"2023060913460065200_CIT0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-019-0557-5","article-title":"Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy","volume":"7","author":"Bergerot","year":"2019","journal-title":"J ImmunoTher Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/6\/494\/50514465\/oyad028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/6\/494\/50514465\/oyad028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T15:01:12Z","timestamp":1686322872000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/6\/494\/7077455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3,14]]},"published-print":{"date-parts":[[2023,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad028","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,3,14]]}}}